Press Releases 2020

  • Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras

    Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras

    LMNL today announced that the first subject has been dosed in the Company’s fezagepras Phase 1 multiple ascending dose clinical trial in healthy volunteers.

    Read Article
  • ×

    Get the updates before everyone else.

    First Name
    Last Name
    * By completing and submitting this form, you understand and agree that use of Liminal BioSciences' web site is subject to Liminal BioSciences Privacy Policy
    !
    Thank you!
    Error - something went wrong!
  • Go to Liminal BioSciences Q1 2021 Results Conference Call on Tuesday May 18, 2021 8:30 AM EST

    View Now
  • Liminal BioSciences Presents Two Case Histories on Investigational Intravenous Plasminogen (Human) Replacement Therapy at The ASH Conference

    Liminal BioSciences Presents Two Case Histories on Investigational Intravenous Plasminogen (Human) Replacement Therapy at The ASH Conference

    LMNL announced the presentation of two scientific posters highlighting potential activity of intravenous Ryplazim® (plasminogen) on infertility and acute airway obstruction in patients with C-PLGD.

    Read Article
  • Liminal Biosciences to Present at The Stifel Virtual Healthcare Conference

    Liminal Biosciences to Present at The Stifel Virtual Healthcare Conference

    LMNL is scheduled to present a company overview at The Stifel 2020 Virtual Healthcare Conference on Monday 16th November at 2:40-3:10 PM (EDT)

    Read Article
  • Liminal BioSciences Reports Third Quarter Financial Results

    Liminal BioSciences Reports Third Quarter Financial Results

    LMNL today reported its unaudited financial results for the third quarter ended September 30, 2020.

    Read Article
  • Liminal Biosciences to Reschedule Reporting of Q3 2020 Results and Conference Call

    Liminal Biosciences to Reschedule Reporting of Q3 2020 Results and Conference Call

    LMNL will now report its financial results for the third quarter ended September 30th 2020 on Thursday November 12, 2020 after market close.

    Read Article
  • Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim® (plasminogen) BLA

    Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim® (plasminogen) BLA

    PDUFA date extended by FDA from March 5, 2021 to June 5, 2021 Earnings call moved forward to Wednesday November 11th

    Read Article
  • Liminal Biosciences To Report Q3 2020 Results And Hold Conference Call

    Liminal Biosciences To Report Q3 2020 Results And Hold Conference Call

    LMNL will report its financial results for the third quarter ended September 30th 2020 on Thursday November 12, 2020 after market close.

    Read Article
  • Liminal BioSciences Announces Upcoming Presentations for Ryplazim® (plasminogen) at the 62nd ASH Annual Meeting and Exposition

    Liminal BioSciences Announces Upcoming Presentations for Ryplazim® (plasminogen) at the 62nd ASH Annual Meeting and Exposition

    LMNL announced the acceptance of two abstracts related to the Company’s clinical development activities of Ryplazim®

    Read Article
  • Liminal BioSciences Announces Private Placement Financing of USD$30 Million

    Liminal BioSciences Announces Private Placement Financing of USD$30 Million

    LMNL entered into a private placement led by an undisclosed leading U.S. public investment fund specializing in life sciences as well as an existing investor, Structured Alpha LP.

    Read Article
  • Liminal BioSciences Provides Update on Progress on BLA for Ryplazim® (plasminogen)

    Liminal BioSciences Provides Update on Progress on BLA for Ryplazim® (plasminogen)

    The FDA confirmed that the resubmission is a complete, Class 2 response and has provided a Prescription Drug User Fee Act ("PDUFA") target action date of March 5, 2021.

    Read Article
  • Liminal Biosciences to Present at The H.C. Wainwright 22nd Annual Global Investment Conference

    Liminal Biosciences to Present at The H.C. Wainwright 22nd Annual Global Investment Conference

    LMNL announced that Kenneth Galbraith, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at The H.C. Wainwright 22nd Annual Global Investment Conference

    Read Article
  • Liminal BioSciences Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Ryplazim® (plasminogen)

    Liminal BioSciences Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Ryplazim® (plasminogen)

    Liminal, through its U.S. subsidiary Prometic Biotherapeutics Inc., has filed a resubmission of the Biologics License Application (BLA) for Ryplazim® (plasminogen) (Ryplazim®) with the U.S. FDA

    Read Article
  • Liminal BioSciences Announces New Appointments to its Board of Directors

    Liminal BioSciences Announces New Appointments to its Board of Directors

    LMNL announced today the appointment of Mr. Alek Krstajic and Mr. Eugene Siklos to the Board of Directors, effective immediately.

    Read Article
  • Liminal BioSciences reports financial results for Q2-2020

    Liminal BioSciences reports financial results for Q2-2020

    Read Article
  • Liminal Biosciences to Present at Canaccord 40th Annual Growth Conference

    Liminal Biosciences to Present at Canaccord 40th Annual Growth Conference

    Liminal BioSciences is scheduled to present a company overview at Canaccord 40th Annual Growth Conference on Thursday 13th August 2:00-2:25 PM (EDT)

    Read Article
  • Liminal Biosciences to Voluntarily Delist from the Toronto Stock Exchange

    Liminal Biosciences to Voluntarily Delist from the Toronto Stock Exchange

    LMNL announces that it has applied for a voluntarily delisting of its common shares (“Common Shares”) from the Toronto Stock Exchange (“TSX”) in Canada.

    Read Article
  • Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program For Eosinophilic-Driven Diseases

    Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program For Eosinophilic-Driven Diseases

    Read Article
  • Liminal BioSciences Joins CoVIg Plasma Alliance to Contribute to Development of Potential New COVID-19 Therapy

    Liminal BioSciences Joins CoVIg Plasma Alliance to Contribute to Development of Potential New COVID-19 Therapy

    LMNL announced that Prometic Plasma Resources, a subsidiary of Liminal BioSciences Inc., has joined the CoVIg-19 Plasma Alliance.

    Read Article
  • Liminal BioSciences Commences Collection of Convalescent Plasma from COVID-19 Recovered Donors

    Liminal BioSciences Commences Collection of Convalescent Plasma from COVID-19 Recovered Donors

    LMNL today announced that Prometic Plasma Resources, a subsidiary of Liminal BioSciences, has commenced the collection of convalescent plasma from donors who have recovered from COVID-19.

    Read Article
  • Liminal BioSciences Provides Guidance on Certain Expected Key Milestones For 2020

    Liminal BioSciences Provides Guidance on Certain Expected Key Milestones For 2020

    LMNL today provided a guidance update on the timing of certain expected key milestones for 2020

    Read Article
  • loading
    Loading More...